Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Martin, Peter [1 ]
Goy, Andre [2 ]
Ramchandren, Radhakrishnan [3 ]
Ferrante, Lucille [4 ]
Reddy, Vijay [4 ]
Londhe, Anil [4 ]
Wildgust, Mark [5 ]
McGowan, Tracy [4 ]
Bartlett, Nancy L. [6 ]
机构：
[1] Weill Cornell Med Coll, New York, NY USA
[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Janssen Sci Affairs LLC, Horsham, PA USA
[5] Janssen Global Serv, Raritan, NJ USA
[6] Washington Univ, Sch Med, St Louis, MO USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma
    Chari, Ajai
    Mark, Tomer M.
    Krishnan, Amrita
    Stockerl-Goldstein, Keith
    Usmani, Saad Z.
    Londhe, Anil
    Etheredge, Delores
    Parros, Hollee
    Fleming, Sarah
    Liu, Baolian
    Freeman, Scott
    Ukropec, Jon
    Lin, Thomas
    Lonial, Sagar
    BLOOD, 2016, 128 (22)
  • [2] A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
    Martin, Peter
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ferrante, Lucille
    Londhe, Anil
    McGowan, Tracy
    Bartlett, Nancy L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 1027 - 1030
  • [3] SIMULATION MODEL OF IBRUTINIB IN TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
    Peng, S.
    Sorensen, S.
    Pan, F.
    Dorman, E.
    Sun, S.
    Van Sanden, S.
    Sengupta, N.
    Gaudig, M.
    VALUE IN HEALTH, 2014, 17 (07) : A620 - A620
  • [4] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Shibayama, Hirohiko
    Choi, Ilseung
    Hatake, Kiyohiko
    Uchida, Toshiki
    Nishikori, Momoko
    Kinoshita, Tomohiro
    Matsuno, Yoshihiro
    Nishikawa, Tomoaki
    Takahara, Satoko
    Tobinai, Kensei
    CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
  • [5] Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Lonial, Sagar
    Mark, Tomer M.
    Krishnan, Amrita Y.
    Stockerl-Goldstein, Keith E.
    Usmani, Saad Z.
    Londhe, Anil
    Etheredge, Delores
    Fleming, Sarah
    Liu, Baolian
    Ukropec, Jon
    Lin, Thomas S.
    Jagannath, Sundar
    Nooka, Ajay K.
    CANCER, 2018, 124 (22) : 4342 - 4349
  • [6] Results of the Daratumumab Monotherapy Early Access Treatment Protocol (EAP) in Patients from Brazil With Relapsed or Refractory Multiple Myeloma
    Crusoe, Edvan de Queiroz
    Pimenta, Flavia
    Maiolino, Angelo
    Rocha, Vanderson
    de Castro, Nelson Siqueira
    Pei, Huiling
    Trufelli, Damila
    Fernandez, Mariana
    Herriot, Luciana Barreto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E246 - E247
  • [7] Efficacy and Safety Of Treatments For Relapsed Or Refractory Mantle Cell Lymphoma (MCL): Results Of a Systematic Literature Review
    Njue, Annete
    Trask, Peter C.
    Colosia, Ann
    Olivares, Robert
    Khan, Shahnaz
    Abbe, Adeline
    Police, Rachel Lee
    Wang, Jianmin
    Sherrill, Elizabeth
    Kaye, James A.
    Awan, Farrukh T.
    BLOOD, 2013, 122 (21)
  • [8] Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)
    Chiattone, Carlos Sergio
    Hamerschlak, Nelson
    Fogliatto, Laura
    Scheinberg, Phillip
    Bigni, Ricardo
    Rodrigues, Celso
    Garicochea, Bernardo
    Pimenta, Alex
    Boechat, Tiago Oliveira
    Musacchio, Juliane
    Bortolini, Jaisson
    Goncalves, Iara Zapparoli
    Matias Vieira, Garles Miller
    Buccheri, Valeria
    Santos, Telma
    Grings, Mariana
    Parisi, Lori
    Barreyro, Paula
    BLOOD, 2018, 132
  • [9] ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO
    Carlos, F.
    Herrera, M.
    Salazar, A.
    Aguirre, A.
    Gonzalez-Michaca, L.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
  • [10] Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    Balasubramanian, Sriram
    Schaffer, Michael
    Deraedt, William
    Davis, Cuc
    Stepanchick, Emily
    Aquino, Regina
    Yuan, Zhilong
    Kranenburg, Britte
    Avivi, Irit
    Dreyling, Martin
    Rule, Simon
    Wang, Michael
    Zhuang, Sen Hong
    Rizo, Aleksandra
    Lenz, Georg
    BLOOD, 2014, 124 (21)
12345